A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug

A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug

Source: 
Fierce Biotech
snippet: 

Day One Biopharmaceuticals appears to be living up to its namesake of altering pediatric cancer care from day one, unveiling positive initial data for its brain tumor drug that saw its share price double on Monday morning.